mirvetuximab soravtansine-gynx injection
mirvetuximab soravtansine-gynx injection
for intravenous use Initial U.S. Approval: 2022
Elahere (mirvetuximab soravtansine-gynx) is an antibody-drug conjugate (ADC) and microtubule inhibitor indicated for treatment of FR-alfa positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Facts about mirvetuximab soravtansine-gynx injection
Approval Date: 11/14/2022
Proprietary Name: Elahere
Active Ingredient(s): mirvetuximab soravtansine-gynx
FDA-approved use: To treat patients with recurrent ovarian cancer that is resistant to platinum therapy
Dosage Form: Injection
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “mirvetuximab soravtansine-gynx injection” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
info@indianpharmanetwork.co.in
FAX NUMBER:
+91-11-26532129
Query For mirvetuximab soravtansine-gynx injection
Approved accessible "mirvetuximab soravtansine-gynx injection"
Mirvetuximab soravtansine is indicated for the treatment of adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Recipients are selected for therapy based on an FDA-approved test.
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for fallopian tube cancer or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.Mirvetuximab soravtansine was approved for medical use in the United States in November 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
How can 1 go about obtaining mirvetuximab soravtansine-gynx injection?
If mirvetuximab soravtansine-gynx injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
Elahere (mirvetuximab soravtansine-gynx) injection for intravenous use Initial U.S. Approval: 2022
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in